The Global Genes Next 2021 Report: A Time for Resilience and Ingenuity, written by Daniel Levine is complete and available from Global Genes. The report covers major developments of 2020 and the top trends that are reshaping the rare disease landscape. Click the link below to access the report.
Related
Continuing Advocacy and Expanding Research Efforts: Global Genes 2023 Impact Report
To our community members: For both the rare disease community and Global Genes, 2023 marked a year […]
Read moreGlobal Genes 2023 RARE Impact Grants Report
Over the past decade, Global Genes’ RARE Impact Grant Program has provided grants to rare disease patient […]
Read moreNEXT Report 2024: Rewriting the Rules
Over the past year, technological advances in rare disease drug and therapy development, coupled with the tenacity of rare disease patients and advocates, have prevailed despite the challenges of financial difficulties in biopharma. Next-generation patient advocates continue to take an active role in drug development, as outlined in the 2024 NEXT Report.
Read moreGlobal Genes 2022 RARE Impact Grants Report
Over the past decade, Global Genes’ RARE Impact Grant Program has provided funding opportunities for rare patient […]
Read moreRARE-X Insights & Recommendations for Organizational DEI Strategies Study
Ensuring diversity, equity, and inclusion in rare disease organizations requires focused programs that engage all stakeholders. A […]
Read moreRARE Health Equity Report: Building a More Inclusive Rare Disease Community
For communities of color and other minoritized populations, finding and connecting with others in their disease community, […]
Read more2022 Rare Disease Drug Development Report: Collaborate to Accelerate
In June 2022, Global Genes partnered with the Orphan Drug Center of the University of Pennsylvania to […]
Read more2019 NEXT: Imagining the Future of Rare Disease
The pace of innovation continues to accelerate, thanks in no small measure to the growing sophistication of […]
Read moreRARE Drug Development 2020 Report
RARE Drug Development Report This year began with hope for the future and advancements in rare […]
Read more